{"id":"sglt2-inhibition","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Genital mycotic infections"},{"rate":"3-8","effect":"Urinary tract infections"},{"rate":"2-5","effect":"Polyuria"},{"rate":"0.1-0.2","effect":"Diabetic ketoacidosis"},{"rate":"2-4","effect":"Volume depletion"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SGLT2 inhibitors work by inhibiting the SGLT2 transporter protein located in the proximal tubule of the kidney. This prevents the reabsorption of filtered glucose, leading to increased urinary glucose excretion (glucosuria) and lowering of blood glucose levels. Beyond glycemic control, these agents provide cardiovascular and renal protective effects through mechanisms including osmotic diuresis, improved insulin sensitivity, and reduced intraglomerular pressure.","oneSentence":"SGLT2 inhibitors block sodium-glucose cotransporter 2 in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:07:53.421Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Chronic kidney disease"}]},"trialDetails":[{"nctId":"NCT07018622","phase":"PHASE2","title":"Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity","status":"RECRUITING","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2025-05-07","conditions":"Solid Tumors, Cisplatin Nephrotoxicity","enrollment":46},{"nctId":"NCT05179668","phase":"PHASE2","title":"SGLT2 Inhibition in Hemodialysis","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2022-10-01","conditions":"Kidney Failure, Hemodialysis, Diabetes Mellitus, Type 2","enrollment":220},{"nctId":"NCT07280585","phase":"PHASE3","title":"STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease","status":"RECRUITING","sponsor":"University of Cologne","startDate":"2025-12-16","conditions":"Polycystic Kidney, Autosomal Dominant","enrollment":420},{"nctId":"NCT04906213","phase":"PHASE2","title":"CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients","status":"TERMINATED","sponsor":"Duke University","startDate":"2022-07-25","conditions":"Kidney Transplant; Complications, Diabetes Mellitus, Type 2","enrollment":20},{"nctId":"NCT05885607","phase":"","title":"Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure","status":"ENROLLING_BY_INVITATION","sponsor":"University of Pennsylvania","startDate":"2023-06-27","conditions":"Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure","enrollment":40},{"nctId":"NCT06506422","phase":"PHASE2, PHASE3","title":"Empagliflozin Reversal of Arterial StiffnEss in Aging","status":"RECRUITING","sponsor":"University of Missouri-Columbia","startDate":"2024-08-18","conditions":"Aging, Arterial Stiffness","enrollment":80},{"nctId":"NCT06355310","phase":"PHASE2","title":"Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease","status":"RECRUITING","sponsor":"Justin Ryder","startDate":"2025-04-10","conditions":"Non-Alcoholic Fatty Liver Disease","enrollment":40},{"nctId":"NCT06804161","phase":"PHASE3","title":"SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension","status":"RECRUITING","sponsor":"Prof. Dr. med. Ingo Eitel","startDate":"2025-12-10","conditions":"Atrial Hypertension","enrollment":3000},{"nctId":"NCT05856760","phase":"PHASE2","title":"A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN","status":"COMPLETED","sponsor":"Travere Therapeutics, Inc.","startDate":"2023-05-19","conditions":"Immunoglobulin A Nephropathy","enrollment":48},{"nctId":"NCT06745063","phase":"PHASE2","title":"Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2025-05-30","conditions":"Obesity, Vascular Health","enrollment":50},{"nctId":"NCT05090358","phase":"PHASE2","title":"Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-10-08","conditions":"Breast Cancer, Breast Cancer Stage IV, Metastatic Breast Cancer","enrollment":15},{"nctId":"NCT04887935","phase":"PHASE1","title":"Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-06-04","conditions":"Prostate Cancer, Cancer of Prostate","enrollment":24},{"nctId":"NCT05468203","phase":"PHASE3","title":"PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care","status":"RECRUITING","sponsor":"The George Institute","startDate":"2023-11-29","conditions":"Acute Kidney Injury","enrollment":3000},{"nctId":"NCT07143773","phase":"PHASE4","title":"SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2025-09-01","conditions":"Kidney Transplantation Recipients, Sodium-Glucose Transporter 2 Inhibitors, Non-Diabetic Patients","enrollment":88},{"nctId":"NCT06054035","phase":"PHASE4","title":"SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2023-10-26","conditions":"Type2diabetes, PreDiabetes, Renal Failure","enrollment":170},{"nctId":"NCT07070765","phase":"NA","title":"Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity","status":"NOT_YET_RECRUITING","sponsor":"University of Aberdeen","startDate":"2025-11-01","conditions":"Breast Cancer","enrollment":70},{"nctId":"NCT05507892","phase":"PHASE2","title":"Renal Mechanism of SGLT2 Inhibition","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2022-10-10","conditions":"Type 2 Diabetes, Diabetic Kidney Disease","enrollment":40},{"nctId":"NCT04735042","phase":"","title":"SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2020-10-07","conditions":"Type 2 Diabetes, Urinary Tract Infections","enrollment":60},{"nctId":"NCT07060417","phase":"PHASE2","title":"Vascular Effects of SGLT2i in Non-diabetic CKD","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-04-01","conditions":"Non-diabetic Chronic Kidney Disease","enrollment":52},{"nctId":"NCT03919656","phase":"PHASE4","title":"SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2019-05-12","conditions":"Type 2 Diabetes Mellitus","enrollment":60},{"nctId":"NCT05972564","phase":"PHASE1, PHASE2","title":"The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-09-06","conditions":"Obesity, Metabolic Syndrome","enrollment":74},{"nctId":"NCT05966792","phase":"NA","title":"SGLT2 Inhibitors in Treating Patients With PCOS","status":"ENROLLING_BY_INVITATION","sponsor":"Shanghai 10th People's Hospital","startDate":"2023-11-10","conditions":"Polycystic Ovary Syndrome","enrollment":80},{"nctId":"NCT05590143","phase":"PHASE4","title":"proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amsterdam UMC","startDate":"2023-06-09","conditions":"Acute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 Inhibitor","enrollment":784},{"nctId":"NCT05884866","phase":"PHASE2","title":"A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.","status":"RECRUITING","sponsor":"Klinikum Nürnberg","startDate":"2023-07-13","conditions":"Chronic Renal Failure, Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis, Chronic Kidney Disease Stage 3","enrollment":100},{"nctId":"NCT06955260","phase":"PHASE3","title":"SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure","status":"NOT_YET_RECRUITING","sponsor":"Subodh Verma","startDate":"2025-05","conditions":"Congenital Heart Disease","enrollment":410},{"nctId":"NCT06929169","phase":"PHASE2","title":"Cardiovascular Effects of SGLT2 Inhibitors in Hemodialysis Patients: A Phase 2 Randomized Study","status":"RECRUITING","sponsor":"Maximo Agustin Schiavone","startDate":"2025-05","conditions":"Chronic Kidney Disease Requiring Hemodialysis","enrollment":80},{"nctId":"NCT05938712","phase":"PHASE2","title":"The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-10-24","conditions":"Kidney Transplant Recipients","enrollment":20},{"nctId":"NCT05715814","phase":"PHASE3","title":"meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2024-09-01","conditions":"Peritoneal Dialysis Complication, End Stage Kidney Disease, Sodium-glucose Co-transporter-2 Inhibitors","enrollment":20},{"nctId":"NCT05792540","phase":"PHASE2","title":"Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-06-06","conditions":"Depressive Disorder","enrollment":75},{"nctId":"NCT05305911","phase":"PHASE2","title":"Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI","status":"RECRUITING","sponsor":"Minneapolis Heart Institute Foundation","startDate":"2022-08-03","conditions":"Heart Attack, Enlarged Heart","enrollment":81},{"nctId":"NCT06291155","phase":"PHASE4","title":"Mechanism of SGLT2 Inhibition in the Kidney","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2024-01-01","conditions":"Type 2 Diabetes, Diabetic Kidney Disease","enrollment":20},{"nctId":"NCT04401904","phase":"PHASE1, PHASE2","title":"SGLT2 Inhibition in Older Obese Adults With Pre-diabetes","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2020-06-25","conditions":"Aging","enrollment":20},{"nctId":"NCT04907214","phase":"PHASE1, PHASE2","title":"SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2021-07-29","conditions":"Obesity, Pre-diabetes","enrollment":29},{"nctId":"NCT03782259","phase":"PHASE4","title":"Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2","status":"COMPLETED","sponsor":"University of Washington","startDate":"2019-02-26","conditions":"Type 2 Diabetes Mellitus, Myocardial Fibrosis, Myocardial Inflammation","enrollment":62},{"nctId":"NCT06140251","phase":"","title":"Investigation of Biomarker Response to SGLT2 Inhibition in Heart Failure","status":"UNKNOWN","sponsor":"Queen's University, Belfast","startDate":"2023-08-21","conditions":"Heart Failure","enrollment":68},{"nctId":"NCT04049110","phase":"PHASE3","title":"Dapagliflozin in Physical Exercise in Type 1 Diabetes","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2020-08-25","conditions":"Diabetes Mellitus, Type 1","enrollment":39},{"nctId":"NCT05417646","phase":"NA","title":"Impact of SGLT2 on Glucosuria in HNF1A-MODY","status":"COMPLETED","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2022-06-22","conditions":"Maturity-Onset Diabetes of the Young, Type 3, Type 2 Diabetes","enrollment":21},{"nctId":"NCT03331289","phase":"PHASE4","title":"Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2018-02-28","conditions":"Diabetes Mellitus, Type 2","enrollment":107},{"nctId":"NCT04258371","phase":"PHASE2","title":"DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2020-02-10","conditions":"Cardiovascular Risk Factor","enrollment":50},{"nctId":"NCT04535960","phase":"PHASE2","title":"Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: \"NATRIURETIC\" Trial","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2019-01-24","conditions":"Type 2 Diabetes Mellitus","enrollment":36},{"nctId":"NCT05210517","phase":"PHASE4","title":"SGLT2 Inhibition: Uric Acid Excretion Study","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2020-10-01","conditions":"Type 2 Diabetes","enrollment":10},{"nctId":"NCT04542291","phase":"PHASE1","title":"Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2021-02-25","conditions":"Pancreas Cancer, Pancreatic Cancer, Cancer of the Pancreas","enrollment":15},{"nctId":"NCT03714594","phase":"PHASE2","title":"Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2018-07-24","conditions":"Type2 Diabetes Mellitus","enrollment":48},{"nctId":"NCT02796170","phase":"PHASE4","title":"Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tulane University School of Medicine","startDate":"2016-03","conditions":"Type 2 Diabetes, Hypertension","enrollment":11},{"nctId":"NCT03912909","phase":"PHASE4","title":"Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans","status":"UNKNOWN","sponsor":"Royal Perth Hospital","startDate":"2018-08-01","conditions":"Metabolic Syndrome, Type 2 Diabetes Mellitus, Obesity","enrollment":30},{"nctId":"NCT04700839","phase":"PHASE4","title":"SGLT2 Inhibitors in Patients With PCOS","status":"COMPLETED","sponsor":"Shanghai 10th People's Hospital","startDate":"2020-05-01","conditions":"Polycystic Ovary Syndrome","enrollment":68},{"nctId":"NCT03979352","phase":"PHASE3","title":"Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient Setting","status":"COMPLETED","sponsor":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital","startDate":"2019-08-01","conditions":"Type1 Diabetes Mellitus","enrollment":28},{"nctId":"NCT05250752","phase":"PHASE2","title":"Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment","status":"UNKNOWN","sponsor":"Holbaek Sygehus","startDate":"2021-11-18","conditions":"End Stage Renal Disease, Peritoneal Dialysis Complication","enrollment":10},{"nctId":"NCT04238702","phase":"PHASE4","title":"Renohemodynamic Effects of Combined empagliflOzin and LosARtan","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2020-11-04","conditions":"Diabetes Mellitus, Type 2, Diabetic Kidney Disease","enrollment":24},{"nctId":"NCT04143581","phase":"PHASE2","title":"SGLT2 Inhibitors in Glomerular Hyperfiltration","status":"WITHDRAWN","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-09-03","conditions":"Obesity, Non-diabetic Chronic Kidney Disease","enrollment":""},{"nctId":"NCT04200586","phase":"PHASE4","title":"The Effects of SGLTi on Diabetic Cardiomyopathy","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2020-04-09","conditions":"Type2 Diabetes, Heart Failure With Reduced Ejection Fraction","enrollment":30},{"nctId":"NCT03226457","phase":"PHASE4","title":"SGLT2 Inhibition in Combination With Diuretics in Heart Failure","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2017-12-11","conditions":"Heart Failure, Type 2 Diabetes Mellitus","enrollment":23},{"nctId":"NCT03510000","phase":"NA","title":"Alleviating Carbohydrate-Counting Burden in T1DM Using Artificial Pancreas and Empagliflozin","status":"COMPLETED","sponsor":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital","startDate":"2018-05-15","conditions":"Type1diabetes","enrollment":30},{"nctId":"NCT03361098","phase":"PHASE4","title":"DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2017-09-18","conditions":"Type 2 Diabetes Mellitus, Obesity","enrollment":65},{"nctId":"NCT03313752","phase":"PHASE3","title":"Effects of SGLT2 Inhibition on Myocardial Insulin Sensitivity","status":"UNKNOWN","sponsor":"Andrea Giaccari","startDate":"2017-12-01","conditions":"Type2 Diabetes Mellitus, Stable Coronary Artery Disease","enrollment":52},{"nctId":"NCT04739215","phase":"PHASE4","title":"Effects of SGLT2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With HFpEF","status":"UNKNOWN","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2021-01-15","conditions":"Diabetes Mellitus, Type 2, Heart Failure With Preserved Ejection Fraction","enrollment":62},{"nctId":"NCT04193566","phase":"PHASE4","title":"Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes","status":"COMPLETED","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2020-02-01","conditions":"Nephropathy, Hypoxia, Mitochondrial Alteration","enrollment":30},{"nctId":"NCT02592421","phase":"PHASE3","title":"SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2015-10-23","conditions":"Type II Diabetes Mellitus","enrollment":30},{"nctId":"NCT03168295","phase":"PHASE4","title":"PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2016-10","conditions":"Diabetes Mellitus, Type 2","enrollment":34},{"nctId":"NCT03254849","phase":"PHASE4","title":"Empagliflozin and Sympathetic Nerve Traffic","status":"COMPLETED","sponsor":"Profil Institut für Stoffwechselforschung GmbH","startDate":"2017-12-08","conditions":"Type 2 Diabetes Mellitus","enrollment":75},{"nctId":"NCT02682563","phase":"PHASE4","title":"Renoprotective Effects of Dapagliflozin in Type 2 Diabetes","status":"COMPLETED","sponsor":"M.H.H. Kramer","startDate":"2016-02","conditions":"Diabetes Mellitus, Type 2, Diabetic Nephropathies","enrollment":44},{"nctId":"NCT04215445","phase":"PHASE4","title":"Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKD","status":"UNKNOWN","sponsor":"National University of Malaysia","startDate":"2019-12-01","conditions":"Diabetic Retinopathy, Chronic Kidney Diseases, Diabetes Mellitus","enrollment":90},{"nctId":"NCT04127084","phase":"PHASE4","title":"Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Zhongshan Hospital Xiamen University","startDate":"2019-10-15","conditions":"Type 2 Diabetes, Diabetic Nephropathy","enrollment":70},{"nctId":"NCT03113110","phase":"PHASE2","title":"Empagliflozin in Post-Transplantation Diabetes Mellitus","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2017-01-15","conditions":"Posttransplant Diabetes Mellitus","enrollment":16},{"nctId":"NCT02728453","phase":"PHASE4","title":"SGLT2 Inhibition and Left Ventricular Mass","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2016-04-27","conditions":"Diabetes Mellitus Type 2","enrollment":7},{"nctId":"NCT02985242","phase":"PHASE4","title":"Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2017-06-12","conditions":"Diabetes Mellitus, Type II","enrollment":6},{"nctId":"NCT02360774","phase":"PHASE4","title":"Mechanisms of Weight Loss With SGLT2 Inhibition","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2015-02","conditions":"Type 2 Diabetes, Overweight, Obesity","enrollment":30},{"nctId":"NCT02397421","phase":"PHASE4","title":"Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2015-03","conditions":"Heart Failure, Diabetes","enrollment":56},{"nctId":"NCT02862067","phase":"","title":"SGLT2 Inhibition in Diabetes and Heart Failure","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2016-07","conditions":"Diabetes Mellitus, Type 2, Heart Failure, Systolic","enrollment":18},{"nctId":"NCT02558270","phase":"PHASE2","title":"Effects of SGLT-2 Inhibition on Hepatic Glucose and Energy Metabolism","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2016-06","conditions":"Type 2 Diabetes, Metabolically Healthy Controls","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":841,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dapagliflozine,Empagliflozin,Canagliflozin"],"phase":"marketed","status":"active","brandName":"SGLT2 Inhibition","genericName":"SGLT2 Inhibition","companyName":"Zhongshan Hospital Xiamen University","companyId":"zhongshan-hospital-xiamen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SGLT2 inhibition is a treatment for conditions such as type 2 diabetes and chronic kidney disease, and it involves the use of medications like dapagliflozin. Dapagliflozin works by inhibiting the sodium-glucose cotransporter 2 (SGLT2), a protein involved in glucose reabsorption in the kidneys.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}